Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Amgen, Arrakis taking the logic of PROTACs to RNA degraders

Michael Gilman-led biotech gets $75M up front in expandable five-target deal uniting platforms

By Paul Bonanos, Associate Editor
January 12, 2022 12:25 AM UTC

For Arrakis’ second major alliance, the RNA-targeting small molecule developer is teaming with Amgen to create what the partners hope will be a new drug class: targeted RNA degraders.

Led by serial entrepreneur Michael Gilman, Arrakis Therapeutics Inc. is tapping into the Induced Proximity Platform, a program at Amgen Inc. (NASDAQ:AMGN) designed to create two-way molecules that induce an effect on a desired target by bringing an effector molecule close enough to strike...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

Arrakis Therapeutics Inc.